Skip to main content
Top
Published in: Abdominal Radiology 4/2005

01-08-2005

Feature Section, Radiofrequency Tumor Ablation, Under The Guest Editorship of A. R. Gillams

Author: Morton A. Meyers

Published in: Abdominal Radiology | Issue 4/2005

Login to get access

Excerpt

Radiofrequency ablation (RFA) of tumors is a therapeutic modality that has been rapidly accepted in academic centers and community hospitals. Although it is currently used for primary and metastatic tumors of the kidney, bones, lungs, breast, and head and neck, it is most commonly used for therapy of unresectable tumors in the liver. Italian researchers have recently suggested that RFA should be offered as first-line therapy for patients with liver tumors. In patients who had cirrhosis and hepatocellular carcinoma controlled only with RFA, 5-year survival rates appeared to be similar, and in some cases superior, to those for surgery. …
Metadata
Title
Feature Section, Radiofrequency Tumor Ablation, Under The Guest Editorship of A. R. Gillams
Author
Morton A. Meyers
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 4/2005
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-004-0292-2

Other articles of this Issue 4/2005

Abdominal Radiology 4/2005 Go to the issue

OriginalPaper

Book review

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.